7,10,13-hexadecatrienoic acid | 1569300-52-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 7,10,13-hexadecatrienoic acid
• 英文别名: C16:3 (tr-7,10,13)；(7E,10E,13E)-hexadeca-7,10,13-trienoic acid
• CAS: 1569300-52-2
• 化学式: C₁₆H₂₆O₂
• 分子量: 250.381
• InChiKey: KBGYPXOSNDMZRV-IUQGRGSQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  18
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7,10,13-hexadecatrienoic acid 、 甲醇 生成 7,10,13-Hexadecatrienoic acid, methyl ester
  参考文献：
  名称：

  REZANKA, TOMAS;PODOJIL, MILOSLAV, J. CHROMATOGR., 463,(1989) N, C. 397-408

  摘要：

  DOI：

文献信息

• [EN] LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS<br/>[FR] PROMÉDICAMENTS LIPIDIQUES ORIENTANT VERS LE SYSTÈME LYMPHATIQUE
  申请人：ARIYA THERAPEUTICS INC

  公开号：WO2019046491A1

  公开（公告）日：2019-03-07

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a provided lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，其制药组合物，制备这种前药和组合物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或症状的方法，包括向需要的患者施用所提供的脂质前药或其制药组合物。
• POLYMER-CARBOHYDRATE CONJUGATES FOR DRUG DELIVERY TECHNOLOGY
  申请人：Wu Nian

  公开号：US20150157721A1

  公开（公告）日：2015-06-11

  The invention comprises compounds, methods of making, and methods of using. The compounds may have a linear or cylic backbone and three or four appended functional groups: one or two lipohilic compounds including sterols or “fat soluble” vitamins, one or two hydrophilic polymer, and one or two carbohydrate. A group of polymer-carbohydrate conjugates having a central backbone and three appended functional groups are disclosed wherein one lipophilic compound is void of both steroid acids. The conjugate may have fatty acids as the primary lipophilic carrier, one hydrophilic polymer, and one carbohydrate. Specific functional groups may be selected for specific applications in formulating pharmaceuticals, cosmetics, nutriceuticals, and the like. Typical coupling reaction of the conjugates may involve one or more or combinations or in series of alkylation including N-alkylation or O-alkylation, etherification, esterification and amidation chemical processes. A variety of linkers between the backbone and functional groups may also be selected to modify the carriers or center backbones for the coupling reactions and optimize performance of the conjugates.

  该发明包括化合物、制备方法和使用方法。这些化合物可能具有线性或环状的骨架，以及三个或四个附加的功能基团：一个或两个疏水化合物，包括固醇或“脂溶性”维生素，一个或两个亲水性聚合物，以及一个或两个碳水化合物。公开了一组具有中心骨架和三个附加功能基团的聚合物-碳水化合物共轭物，其中一个疏水性化合物不含类固醇酸。该共轭物可能以脂肪酸作为主要疏水载体，一个亲水性聚合物和一个碳水化合物。特定的功能基团可以根据在制备药物、化妆品、营养保健品等方面的具体应用而选择。共轭物的典型偶联反应可能涉及一种或多种或组合或串联的烷基化，包括N-烷基化或O-烷基化，醚化，酯化和酰胺化化学过程。还可以选择各种连接剂连接骨架和功能基团之间，以修改载体或中心骨架以进行偶联反应并优化共轭物的性能。
• [EN] FATTY ACID CYSTEAMINE CONJUGATES OF CFTR MODULATORS AND THEIR USE IN TREATING MEDICAL DISORDERS<br/>[FR] CONJUGUÉS DE CYSTÉAMINE D'ACIDE GRAS DE MODULATEURS DE CFTR ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：CATABASIS PHARMACEUTICALS INC

  公开号：WO2016086136A1

  公开（公告）日：2016-06-02

  The invention relates to fatty acid cysteamine conjugates of a CFTR modulator, compositions comprising a fatty acid cysteamine conjugate of a CFTR modulator, and methods for using such conjugates and compositions to treat disease, such as a disease caused by dysregulation of autophagy.

  这项发明涉及一种CFTR调节剂的脂肪酸半胱氨酸共轭物，包括CFTR调节剂的脂肪酸半胱氨酸共轭物的组合物，以及使用这种共轭物和组合物治疗疾病的方法，例如由自噬失调引起的疾病。
• NSAID derivatives of omega-3 polyunsaturated acids as gamma secretase modulators
  申请人：Jiva Pharma, Inc.

  公开号：US10125078B1

  公开（公告）日：2018-11-13

  The present invention relates to the NSAID derivatives of omega-3 fatty acids as gamma secretase modulators and their use in treating Alzheimer's disease, hypertriglyceridemia, and cardiovascular disease by reducing triglycerides, and for use as anti-inflammatory agents.

  本发明涉及 NSAID 衍生物的ω-3脂肪酸作为γ-分泌酶调节剂，并其在治疗阿尔茨海默病、高甘油三酯血症和心血管疾病中的使用，通过降低甘油三酯的含量，并用作抗炎药。
• [EN] FATTY ACID NIACIN CONJUGATES<br/>[FR] CONJUGUÉS ACIDE GRAS NIACINE
  申请人：CATABASIS PHARMACEUTICALS INC

  公开号：WO2015073901A1

  公开（公告）日：2015-05-21

  The invention provides fatty acid niacin conjugates; pharmaceutical compositions comprising an effective amount of the fatty acid niacin conjugate; and methods for treating or preventing a metabolic disease comprising the administration of an effective amount of the fatty acid niacin conjugate.

  这项发明提供了脂肪酸烟酸共轭物；包含有效量脂肪酸烟酸共轭物的药物组合物；以及治疗或预防代谢性疾病的方法，包括给予有效量脂肪酸烟酸共轭物。